Welcome Dr Toru Ishikawa to Open Journal of Gastroenterology and Hepatology.

Dr Toru Ishikawa
Gastroenterology, Saiseikai Niigata Daini Hospital


Biography & Research Interest

Welcome Dr Toru Ishikawa to Join the Editorial Board of Open Journal of Gastroenterology and Hepatology.

Academic History:
1992: Niigata University School of Medicine
2000: M.D. Degree
2002 Head Doctor of Gastroenterology, Saiseikai Niigata Daini Hospital
2007 General Manager of Gastroenterology, Saiseikai Niigata Daini Hospital
Awards:
Hepatology Research Award (The Japan Society of Hepatology2003)

Grant
2003 Hepatology Research Award
2003 Niigata University School of Medicine Third Department of Internal Medicine association Ichida Award
2004 Niigata Prefecture Medical Association Research Grant Awards
2004 Niigata Prefecture Saiseikai Inagaki Award
2006 6th Geriatric Gastroenterology Society Award
2006 Fiscal year endoscope Medical Research Foundation Research Grant B award
2009 Niigata Prefecture Medical Association Academic Award Winner
2009 Fiscal year endoscope Medical Research Foundation Research Grant B award
2011 Niigata Prefecture Saiseikai Chairman Award

Scientific research funding
Ministry of Health, Labour and Welfare Grant-in-Aid for Scientific Research business research group (cancer clinical department)
“Clinical trial that aims to establish a new therapy with intra-arterial infusion chemotherapy and molecular targeted drug combination for advanced or recurrent hepatocellular carcinoma (Phase III), as well as biomarker discovery research to predict the effect (SILIUS)” research team member
Ministry of Health, Labour and Welfare Japan medical research and development mechanism research funding innovative cancer care practical research project
“Unresectable Phase II / III multi-center, aimed to establish a standard therapy with hepatic artery chemoembolization therapy and molecular target drug combination for hepatocellular carcinoma co-clinical trial and discovery research physician-led clinical trial of the biomarker to predict the effect “research team member
“Combination therapy Phase II clinical study of hepatic artery chemoembolization and sorafenib for unresectable hepatocellular carcinoma (TACTICS)” research team member

Research interest:
Hepatocellular carcinoma, Liver cirrhosis, Portal hypertension, Hepatitis, IVR


Certificate

Click to download